Bristol-Myers Squibb Co
10 beaten-up stocks that are candidates for a rebound — but all are not created equal
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks are struggling to hold onto gains Tuesday with the market well off its highest levels of the session. Deeply oversold conditions combined with some […]
Read More
Hard-hit Apple bounces back with the market, and an analyst is divided on our drug stocks
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. Wall Street surged Tuesday on increased hopes of tariff deals, following a wickedly volatile session Monday. The Dow Jones Industrial Average climbed around 1,400 points, or 3.7%. The S […]
Read More
Trump’s tariffs are a new challenge for Big Pharma. Here are the best-positioned stocks
Long-standing trade agreements have largely sheltered the pharmaceutical industry from tariffs but President Donald Trump’s goal of bringing manufacturing back to the United States has put the industry in the administration’s crosshairs. Trump first floated the idea of imposing tariffs of as much as 25% on imported pharmaceuticals in mid-February. Since then, he has repeated […]
Read More
Don’t overlook the impact of pharma tariffs, says an analyst. Where we stand on Bristol Myers
The drug stock is higher over the past month while the S&P 500 has pulled back sharply. Source
Read More
We’re booking profits in a rallying rotation play and using the cash to buy 2 others on the dip
We are making a handful of more trades Tuesday. Selling 75 shares of GE Healthcare at roughly $86 each; following the trade, Jim Cramer’s Charitable Trust will own 550 shares of GEHC, decreasing its weighting to about 1.43% from about 1.62% We are buying 50 shares of TJX at roughly $116; following the trade, the […]
Read More
We’re adding to our position in a sliding stock and booking profits in a 2025 winner
We’re making a pair of trades Monday as Wall Street rallies to kick off the week. Source
Read More
Trump is unlikely to end Medicare drug price talks — here’s what that means for patients and pharma
President Donald Trump arrives in the Brady Press Briefing Room at the White House on Jan. 30, 2025 in Washington, DC. Oliver Contreras | Afp | Getty Images President Donald Trump likely won’t do away with a landmark process that allows Medicare to negotiate drug prices with manufacturers, even as he moves to erase Joe […]
Read More
Bristol Myers’ stock decline in response to weak guidance is a gift to investors
Bristol Myers Squibb on Thursday reported better-than-expected quarterly results, but weak guidance for 2025 sent shares lower. Jim Cramer’s faith in the drugmaker is unshaken. Revenue in the fourth quarter rose 8% year over year to $12.34 billion, well ahead of the $11.57 billion consensus, according to analysts’ estimates compiled by LSEG. Adjusted earnings per […]
Read More
Stocks making the biggest moves premarket: Ford, Eli Lilly, Honeywell, Arm Holdings and more
Check out the companies making headlines in premarket trading. Ford — The automaker’s shares dropped more than 5% in premarket trading after the company issued soft 2025 guidance , citing “headwinds related to market factors.” Ford did beat Wall Street’s fourth-quarter expectations, however. Bristol Myers Squibb — Shares pulled back nearly 6% after its full-year […]
Read More
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, on Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty Images Bristol Myers Squibb on Thursday said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost savings effort to chart a path toward long-term […]
Read More